Lu, Pin
Wang, Shengchun http://orcid.org/0000-0003-2296-1577
Franzen, Carrie A.
Venkataraman, Girish
McClure, Rebecca
Li, Lei
Wu, Wenjun
Niu, Nifang
Sukhanova, Madina http://orcid.org/0000-0002-1843-7038
Pei, Jianming
Baldwin, Donald A.
Nejati, Reza
Wasik, Mariusz A.
Khan, Nadia
Tu, Yifan
Gao, Juehua
Chen, Yihua
Ma, Shuo
Larson, Richard A. http://orcid.org/0000-0001-9168-3203
Wang, Y. Lynn http://orcid.org/0000-0003-0773-1212
Article History
Received: 9 July 2020
Revised: 21 December 2020
Accepted: 25 January 2021
First Online: 18 February 2021
Conflict of interest
: Y.T., Speaker’s bureau for Novartis. S.M., Consultancy for AstraZeneca, Bioverativ, Genentech, Janssen, Kite and Pharmacyclics, Speaker’s bureau for AstraZeneca, Janssen and Pharmacyclics, and research funding from Abbvie, AstraZeneca, Beigene, Pharmacyclics, Juno and Novartis. N.K., advisory board for Pharmacyclics, Jessen and Seattle Genetics, and research funding from Bristol Meyer Squibb. Y.L.W., employment and stock ownership at Incyte Research Institute. All other authors declare no relevant conflicts of interest.